|
1
|
Ciechanover A: The ubiquitin-proteasome
proteolytic pathway. Cell. 79:13–21. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ciechanover A: The ubiquitin-proteasome
pathway: On protein death and cell life. EMBO J. 17:7151–7160.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Baumeister W, Walz J, Zühl F and Seemüller
E: The proteasome: Paradigm of a self-compartmentalizing protease.
Cell. 92:367–380. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Groll M, Ditzel L, Löwe J, Stock D,
Bochtler M, Bartunik HD and Huber R: Structure of 20S proteasome
from yeast at 2.4 A resolution. Nature. 386:463–471. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Barton LF, Runnels HA, Schell TD, Cho Y,
Gibbons R, Tevethia SS, Deepe GS Jr and Monaco JJ: Immune defects
in 28-kDa proteasome activator gamma-deficient mice. J Immunol.
172:3948–3954. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Preckel T, Fung-Leung WP, Cai Z, Vitiello
A, Salter-Cid L, Winqvist O, Wolfe TG, Von Herrath M, Angulo A,
Ghazal P, et al: Impaired immunoproteasome assembly and immune
responses in PA28-/- mice. Science. 286:2162–2165. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Murata S, Kawahara H, Tohma S, Yamamoto K,
Kasahara M, Nabeshima Y, Tanaka K and Chiba T: Growth retardation
in mice lacking the proteasome activator PA28gamma. J Biol Chem.
274:38211–38215. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li X, Lonard DM, Jung SY, Malovannaya A,
Feng Q, Qin J, Tsai SY, Tsai MJ and O’Malley BW: The SRC-3/AIB1
coactivator is degraded in a ubiquitin- and ATP-independent manner
by the REGgamma proteasome. Cell. 124:381–392. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Roessler M, Rollinger W, Mantovani-Endl L,
Hagmann ML, Palme S, Berndt P, Engel AM, Pfeffer M, Karl J,
Bodenmüller H, et al: Identification of PSME3 as a novel serum
tumor marker for colorectal cancer by combining two-dimensional
polyacrylamide gel electrophoresis with a strictly mass
spectrometry-based approach for data analysis. Mol Cell Proteomics.
5:2092–2101. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
He J, Cui L, Zeng Y, Wang G, Zhou P, Yang
Y, Ji L, Zhao Y, Chen J, Wang Z, et al: REGγ is associated with
multiple oncogenic pathways in human cancers. BMC Cancer.
12:752012. View Article : Google Scholar
|
|
11
|
Yu G, Zhao Y, He J, Lonard DM, Mao CA,
Wang G, Li M and Li X: Comparative analysis of REG{gamma}
expression in mouse and human tissues. J Mol Cell Biol. 2:192–198.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tian M, Xiaoyi W, Xiaotao L and Guosheng
R: Proteasomes reactivator REG gamma enchances oncogenicity of
MDA-MB-231 cell line via promoting cell proliferation and
inhibiting apoptosis. Cell Mol Biol (Noisy-le-grand). 55(Suppl):
OL1121–OL1131. 2009.
|
|
13
|
Chen D, Yang X, Huang L and Chi P: The
expression and clinical significance of PA28γ in colorectal cancer.
J Investig Med. 61:1192–1196. 2013.PubMed/NCBI
|
|
14
|
Wang X, Tu S, Tan J, Tian T, Ran L, Rodier
JF and Ren G: REG gamma: A potential marker in breast cancer and
effect on cell cycle and proliferation of breast cancer cell. Med
Oncol. 28:31–41. 2011. View Article : Google Scholar
|
|
15
|
Miyamoto H, Moriishi K, Moriya K, Murata
S, Tanaka K, Suzuki T, Miyamura T, Koike K and Matsuura Y:
Involvement of the PA28gamma-dependent pathway in insulin
resistance induced by hepatitis C virus core protein. J Virol.
81:1727–1735. 2007. View Article : Google Scholar :
|
|
16
|
Moriishi K, Mochizuki R, Moriya K,
Miyamoto H, Mori Y, Abe T, Murata S, Tanaka K, Miyamura T, Suzuki
T, et al: Critical role of PA28gamma in hepatitis C
virus-associated steatogenesis and hepatocarcinogenesis. Proc Natl
Acad Sci USA. 104:1661–1666. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Moriishi K, Shoji I, Mori Y, Suzuki R,
Suzuki T, Kataoka C and Matsuura Y: Involvement of PA28gamma in the
propagation of hepatitis C virus. Hepatology. 52:411–420. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Suzuki R, Moriishi K, Fukuda K, Shirakura
M, Ishii K, Shoji I, Wakita T, Miyamura T, Matsuura Y and Suzuki T:
Proteasomal turnover of hepatitis C virus core protein is regulated
by two distinct mechanisms: A ubiquitin-dependent mechanism and a
ubiquitin-independent but PA28gamma-dependent mechanism. J Virol.
83:2389–2392. 2009. View Article : Google Scholar :
|
|
19
|
Gao G, Wong J, Zhang J, Mao I, Shravah J,
Wu Y, Xiao A, Li X and Luo H: Proteasome activator REGgamma
enhances coxsackieviral infection by facilitating p53 degradation.
J Virol. 84:11056–11066. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Luo H, Zhang J, Cheung C, Suarez A,
McManus BM and Yang D: Proteasome inhibition reduces coxsackievirus
B3 replication in murine cardiomyocytes. Am J Pathol. 163:381–385.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Si X, McManus BM, Zhang J, Yuan J, Cheung
C, Esfandiarei M, Suarez A, Morgan A and Luo H: Pyrrolidine
dithiocarbamate reduces coxsackievirus B3 replication through
inhibition of the ubiquitin-proteasome pathway. J Virol.
79:8014–8023. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ko NL, Taylor JM, Bellon M, Bai XT,
Shevtsov SP, Dundr M and Nicot C: PA28γ is a novel corepressor of
HTLV-1 replication and controls viral latency. Blood. 121:791–800.
2013. View Article : Google Scholar :
|
|
23
|
Anupam R, Datta A, Kesic M, Green-Church
K, Shkriabai N, Kvaratskhelia M and Lairmore MD: Human
T-lymphotropic virus type 1 p30 interacts with REGgamma and
modulates ATM (ataxia telangiectasia mutated) to promote cell
survival. J Biol Chem. 286:7661–7668. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen X, Barton LF, Chi Y, Clurman BE and
Roberts JM: Ubiquitin-independent degradation of cell-cycle
inhibitors by the REGgamma proteasome. Mol Cell. 26:843–852. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Z and Zhang R: Proteasome activator
PA28 gamma regulates p53 by enhancing its MDM2-mediated
degradation. EMBO J. 27:852–864. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li X, Amazit L, Long W, Lonard DM, Monaco
JJ and O’Malley BW: Ubiquitin- and ATP-independent proteolytic
turnover of p21 by the REGgamma-proteasome pathway. Mol Cell.
26:831–842. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu S, Lai L, Zuo Q, Dai F, Wu L, Wang Y,
Zhou Q, Liu J, Liu J, Li L, et al: PKA turnover by the
REGγ-proteasome modulates FoxO1 cellular activity and VEGF-induced
angiogenesis. J Mol Cell Cardiol. 72:28–38. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dong S, Jia C, Zhang S, Fan G, Li Y, Shan
P, Sun L, Xiao W, Li L, Zheng Y, et al: The REGγ proteasome
regulates hepatic lipid metabolism through inhibition of autophagy.
Cell Metab. 18:380–391. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li L, Zhao D, Wei H, Yao L, Dang Y, Amjad
A, Xu J, Liu J, Guo L, Li D, et al: REGγ deficiency promotes
premature aging via the casein kinase 1 pathway. Proc Natl Acad Sci
USA. 110:11005–11010. 2013. View Article : Google Scholar
|
|
30
|
Black DL: Protein diversity from
alternative splicing: A challenge for bioinformatics and
post-genome biology. Cell. 103:367–370. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Luco RF, Allo M, Schor IE, Kornblihtt AR
and Misteli T: Epigenetics in alternative pre-mRNA splicing. Cell.
144:16–26. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
López-Bigas N, Audit B, Ouzounis C, Parra
G and Guigó R: Are splicing mutations the most frequent cause of
hereditary disease? FEBS Lett. 579:1900–1903. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lim KH, Ferraris L, Filloux ME, Raphael BJ
and Fairbrother WG: Using positional distribution to identify
splicing elements and predict pre-mRNA processing defects in human
genes. Proc Natl Acad Sci USA. 108:11093–11098. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Skotheim RI and Nees M: Alternative
splicing in cancer: Noise, functional, or systematic? Int J Biochem
Cell Biol. 39:1432–1449. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
He C, Zhou F, Zuo Z, Cheng H and Zhou R: A
global view of cancer-specific transcript variants by subtractive
transcriptome-wide analysis. PLoS One. 4:e47322009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Omenn GS, Guan Y and Menon R: A new class
of protein cancer biomarker candidates: Differentially expressed
splice variants of ERBB2 (HER2/neu) and ERBB1 (EGFR) in breast
cancer cell lines. J Proteomics. 107:103–112. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fackenthal JD and Godley LA: Aberrant RNA
splicing and its functional consequences in cancer cells. Dis Model
Mech. 1:37–42. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang Z, Feng X, Liu X, Jiang L, Zeng X, Ji
N, Li J, Li L and Chen Q: Involvement of potential pathways in
malignant transformation from oral leukoplakia to oral squamous
cell carcinoma revealed by proteomic analysis. BMC Genomics.
10:3832009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Martelli PL, D’Antonio M, Bonizzoni P,
Castrignanò T, D’Erchia AM, D’Onorio De Meo P, Fariselli P, Finelli
M, Licciulli F, Mangiulli M, et al: ASPicDB: A database of
annotated transcript and protein variants generated by alternative
splicing. Nucleic Acids Res. 39:Database. D80–D85. 2011. View Article : Google Scholar :
|
|
40
|
Castrignanò T, D’Antonio M, Anselmo A,
Carrabino D, D’Onorio De Meo A, D’Erchia AM, Licciulli F, Mangiulli
M, Mignone F, Pavesi G, et al: ASPicDB: A database resource for
alternative splicing analysis. Bioinformatics. 24:1300–1304. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li J and Rechsteiner M: Molecular
dissection of the 11S REG (PA28) proteasome activators. Biochimie.
83:373–383. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang Z and Burge CB: Splicing regulation:
From a parts list of regulatory elements to an integrated splicing
code. RNA. 14:802–813. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fairbrother WG, Yeh RF, Sharp PA and Burge
CB: Predictive identification of exonic splicing enhancers in human
genes. Science. 297:1007–1013. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jiang WP, Sima ZH, Wang HC, Zhang JY, Sun
LS, Chen F and Li TJ: Identification of the involvement of LOXL4 in
generation of keratocystic odontogenic tumors by RNA-Seq analysis.
Int J Oral Sci. 6:31–38. 2014. View Article : Google Scholar :
|
|
45
|
Delahaye NF, Rusakiewicz S, Martins I,
Ménard C, Roux S, Lyonnet L, Paul P, Sarabi M, Chaput N, Semeraro
M, et al: Alternatively spliced NKp30 isoforms affect the prognosis
of gastrointestinal stromal tumors. Nat Med. 17:700–707. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Jiang L, Yang HS, Wang Z, Zhou Y, Zhou M,
Zeng X and Chen QM: ORAOV1-A correlates with poor differentiation
in oral cancer. J Dent Res. 88:433–438. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chène P: Inhibiting the p53-MDM2
interaction: An important target for cancer therapy. Nat Rev
Cancer. 3:102–109. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
48
|
Shangary S and Wang S: Small-molecule
inhibitors of the MDM2-p53 protein-protein interaction to
reactivate p53 function: A novel approach for cancer therapy. Annu
Rev Pharmacol Toxicol. 49:223–241. 2009. View Article : Google Scholar :
|
|
49
|
Ahn JY, Tanahashi N, Akiyama K, Hisamatsu
H, Noda C, Tanaka K, Chung CH, Shibmara N, Willy PJ, Mott JD, et
al: Primary structures of two homologous subunits of PA28, a
gamma-interferon-inducible protein activator of the 20S proteasome.
FEBS Lett. 366:37–42. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kohda K, Ishibashi T, Shimbara N, Tanaka
K, Matsuda Y and Kasahara M: Characterization of the mouse PA28
activator complex gene family: Complete organizations of the three
member genes and a physical map of the approximately 150-kb region
containing the alpha- and beta-subunit genes. J Immunol.
160:4923–4935. 1998.PubMed/NCBI
|
|
51
|
Mao I, Liu J, Li X and Luo H: REGgamma, a
proteasome activator and beyond? Cell Mol Life Sci. 65:3971–3980.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Realini C, Jensen CC, Zhang Z, Johnston
SC, Knowlton JR, Hill CP and Rechsteiner M: Characterization of
recombinant REGalpha, REGbeta, and REGgamma proteasome activators.
J Biol Chem. 272:25483–25492. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Schwarz K, Eggers M, Soza A, Koszinowski
UH, Kloetzel PM and Groettrup M: The proteasome regulator
PA28alpha/beta can enhance antigen presentation without affecting
20S proteasome subunit composition. Eur J Immunol. 30:3672–3679.
2000. View Article : Google Scholar
|
|
54
|
Stohwasser R, Salzmann U, Giesebrecht J,
Kloetzel PM and Holzhütter HG: Kinetic evidences for facilitation
of peptide channelling by the proteasome activator PA28. Eur J
Biochem. 267:6221–6230. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wilk S, Chen WE and Magnusson RP:
Properties of the nuclear proteasome activator PA28gamma
(REGgamma). Arch Biochem Biophys. 383:265–271. 2000. View Article : Google Scholar
|
|
56
|
Yamano T, Murata S, Shimbara N, Tanaka N,
Chiba T, Tanaka K, Yui K and Udono H: Two distinct pathways
mediated by PA28 and hsp90 in major histocompatibility complex
class I antigen processing. J Exp Med. 196:185–196. 2002.
View Article : Google Scholar : PubMed/NCBI
|
